TCT 2021 VIRTUAL EVENT
Preview the agenda below and stop back the week of November 1st to access virtual links for events and add to calendar reminders.
wednesday, October 27
10:00 A.M. ET
SORT Presentation Including Long-term Durability Data
Andrew Sharp
Virtual Session: World Connect Studio
- Durability of Radio-frequency Catheter-based Renal
- Denervation Associated With Lack of Functional Nerve
- Recovery at 6 Months in Normotensive Swine Model
A link to the World Connect Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
World Connect Channel 15 TRANSPARENTThursday, November 4
4:10 P.M. ET
US Patient Preference (PPI) Presentation
Michael Weber
Virtual Session: Innovation Theater
Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension.
Patient Preferences for Interventional versus Pharmaceutical Treatments Among U.S. Adults with Uncontrolled Hypertension.
- Michael Weber
4:47 P.M. ET
SPYRAL HTN Program Update: Latest Data and Next Steps
Dr. David E. Kandzari
Virtual Session: Innovation Theater
The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Breaking Evidence and Next Step
The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Breaking Evidence and Next Step.
- Dr. David E. Kandzari
Friday, November 5
11:00–11:12 A.M. ET
Late Breaking Clinical Trial
Prof. Nicolas Van Mieghem
Virtual Session: Clinical Science Theater
SURTAVI: 5-Year Clinical and Hemodynamic Outcomes Following Transcatheter or Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk.
5-Year Clinical and Hemodynamic Outcomes Following Transcatheter or Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk (SURTAVI).
- Prof. Nicolas Van Mieghem
4:30 P.M. ET
Oral Presentation
Dr. David E. Kandzari
Moderated Poster Station, Halls A-B, Level I
One-Month Dual Antiplatelet Therapy After PCI with Resolute OnyxTM DES: Final 2-Year Results from the Onyx One Clear Study.
One-Month Dual Antiplatelet Therapy After PCI with Resolute OnyxTM DES: Final 2-Year Results from the Onyx One Clear Study.
- Dr. David E. Kandzari
Saturday, November 6
1:00 P.M. ET
Late Breaking Clinical Trial
Firas Zahr
Virtual Session: Clinical Science Theater
Intrepid TMVR Early Feasibility: Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement.
Intrepid TMVR Early Feasibility: Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement.
- Firas Zahr
Preview the agenda below and stop back the week of November 1st to access virtual links for events and add to calendar reminders.
Thursday, November 4
3:00 – 4:00 P.M. ET
Small Annulus, Big Clinical Benefits?
Dr. Howard Herrmann, Dr. Didier Tchétché, Prof. Dr. Mohamed Abdel-Wahab, Dr. Roxana Mehran
Virtual Session: World Connect Studio
A link to the World Connect Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
World Connect Channel 15 OPAQUEfriday, November 5
6:30 – 7:30 A.M. ET
A Heart Team Walks Into a Conference Room...
Dr. Joshua Rovin, Dr. Neal Kleiman, Dr. V. Antoine Keller, Dr. Guilherme Attizzani
Breakfast: Innovation Theater
Virtual Session: Innovation Theater
A link to the Innovation Studio Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
Innovation Studio Channel 15 TRANSPARENT9:00 – 10:00 A.M. ET
Advanced PCI Techniques in Real-world Cases
Virtual Session: World Connect Studio
A link to the World Connect Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
World Connect Channel 15 TRANSPARENT2:00 P.M. ET
Transforming Hypertension: Updates on SPYRAL-HTN Global Clinical Trial Program — SPRYAL HTN
Mahfoud, Böhm, Ribichini, Sharp, Townsend
Virtual Session: World Connect Studio
SPRYAL HTN Clinical Program review including newest data.
A link to the World Connect Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
World Connect Channel 15 TRANSPARENT7:30 P.M. ET
Medtronic Sponsored Reception
Hyatt Regency Orlando
9801 International Dr.
saturday, November 6
6:30 A.M. ET
Transforming Hypertension: From Evidence to Consensus to Practice
Tsioufis, Kandzari, Pathak, Secemsky, Weil
Breakfast: Innovation Theater
Virtual Session: Innovation Theater
U.S. Patient Preference Data, Recent Consensus Statement Review and Patient Selection
A link to the Innovation Studio Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
Innovation Studio Channel 15 TRANSPARENT4:00 – 5:00 P.M. ET
Intrepid Early Experiences
Virtual Session: World Connect Theater
A link to the World Connect Channel will be available the week of November 1 at https://www.medtronic.com/TCT2021.
World Connect Channel 15 TRANSPARENT
Percutaneous Coronary Intervention
Resolute Onyx DES is backed by robust 1-month DAPT evidence in the most complex high bleeding risk (HBR) patients.1
View Supporting Data
TAVR
The Evolut™ TAVR supra-annular, self-expanding valve design delivers better hemodynamics—that go above and beyond.2
See the Hemodynamic Advantage
TMVR
APOLLO Pivotal Trial is now enrolling in the US.
CAUTION: Investigational device. Limited by Federal Law (USA) to investigational use. Exclusively for clinical investigations.
Learn more about the trial
Cardiac Pacing Therapies
Medtronic is dedicated to providing continuous innovation and technological advancements in transcatheter cardiac pacing.
View Product InformationKandzari DE, Kirtane AJ, Windecker S, et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv. November 2020;13(11):e009565.
Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthesis aortic valve replacement. Heart. May 2008;94(5):637-641
Presented by Thomas Zeller, M.D., at VIVA 2020.